These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24977459)

  • 1. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
    Constantine GD; Goldstein SR; Archer DF
    Menopause; 2015 Jan; 22(1):36-43. PubMed ID: 24977459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
    Simon JA; Lin VH; Radovich C; Bachmann GA;
    Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
    J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J; Portman D; Mabey RG;
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
    Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
    Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
    Goldstein SR; Bachmann GA; Koninckx PR; Lin VH; Portman DJ; Ylikorkala O;
    Climacteric; 2014 Apr; 17(2):173-82. PubMed ID: 23984673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
    Constantine G; Graham S; Portman DJ; Rosen RC; Kingsberg SA
    Climacteric; 2015 Apr; 18(2):226-32. PubMed ID: 25252699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
    Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
    Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.
    Goldstein I; Simon JA; Kaunitz AM; Altomare C; Yoshida Y; Zhu J; Schaffer S; Soulban G
    Menopause; 2019 Sep; 26(9):994-1001. PubMed ID: 31453961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():93-100. PubMed ID: 30509754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
    Bruyniks N; Biglia N; Palacios S; Mueck AO
    Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.